Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 21 July 2009
Vol. 2, Issue 80, p. pe42
[DOI: 10.1126/scisignal.280pe42]

PERSPECTIVES

Thwarting Dyskinesia by Targeting mTORC1

Eric Klann*

Center for Neural Science, New York University, New York, NY 10003, USA.

Abstract: In a mouse model of Parkinson’s disease, new evidence shows that L-DOPA, which is used to treat the symptoms of the disease but also causes dyskinesia, results in a persistent activation of the protein kinase mTOR (mammalian target of rapamycin) in a subset of striatal medium spiny neurons. Moreover, blockade of a specific type of mTOR signaling (mTORC1) prevents the development of dyskinesia, but not the antiakinetic benefits produced by L-DOPA. Thus, mTORC1 may be a viable therapeutic target for dyskinesia caused by L-DOPA treatment in patients with Parkinson’s disease.

* Corresponding author. E-mail, eklann{at}cns.nyu.edu

Citation: E. Klann, Thwarting Dyskinesia by Targeting mTORC1. Sci. Signal. 2, pe42 (2009).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Science Signaling Podcast: 21 July 2009.
W. Wong and A. M. VanHook (2009)
Science Signaling 2, pc13
   Abstract »    Full Text »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882